Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7P85

Engineered phosphotriesterase BdPTE 10-2-C3(C59V/C227V) in complex with ethyl-4-methylbenzylphosphonate

7P85 の概要
エントリーDOI10.2210/pdb7p85/pdb
関連するPDBエントリー1PSC
分子名称Parathion hydrolase, ethyl-4-methylbenzylphosphonate, FORMIC ACID, ... (7 entities in total)
機能のキーワードbioscavenger, enzyme engineering, organophosphate hydrolase, organophosphorous compound, phosphotriesterase, hydrolase
由来する生物種Brevundimonas diminuta (Pseudomonas diminuta)
タンパク質・核酸の鎖数1
化学式量合計38639.95
構造登録者
Eichinger, A.,Skerra, A. (登録日: 2021-07-21, 公開日: 2022-08-03, 最終更新日: 2024-02-07)
主引用文献Job, L.,Kohler, A.,Eichinger, A.,Testanera, M.,Escher, B.,Worek, F.,Skerra, A.
Structural and Functional Analysis of a Highly Active Designed Phosphotriesterase for the Detoxification of Organophosphate Nerve Agents Reveals an Unpredicted Conformation of the Active Site Loop.
Biochemistry, 62:942-955, 2023
Cited by
PubMed Abstract: Neurotoxic organophosphorus compounds (OPs) pose a severe threat if misused in military conflicts or by terrorists. Administration of a hydrolytic enzyme that can decompose the circulating nerve agent into non-toxic metabolites in vivo offers a potential treatment. A promising candidate is the homo-dimeric phosphotriesterase originating from the bacterium (BdPTE), which has been subject to several rational and combinatorial protein design studies. A series of engineered versions with much improved catalytic efficiencies toward medically relevant nerve agents was described, carrying up to 22 mutations per enzyme subunit. To provide a basis for further rational design, we have determined the crystal structure of the highly active variant 10-2-C3(C59V/C227V)─stabilized against oxidation by substitution of two unpaired Cys residues─in complex with a substrate analogue at 1.5 Å resolution. Unexpectedly, the long loop segment (residues 253-276) that covers the active site shows a totally new conformation, with drastic structural deviations up to 19 Å, which was neither predicted in any of the preceding protein design studies nor seen in previous crystallographic analyses of less far evolved enzyme versions. Inspired by this structural insight, additional amino acid exchanges were introduced and their effects on protein stability as well as on the catalytic efficiency toward several neurotoxic OPs were investigated. Somewhat surprisingly, our results suggest that the presently available engineered version of BdPTE, in spite of its design on the basis of partly false structural assumptions, constitutes a fairly optimized enzyme for the detoxification of relevant OP nerve agents.
PubMed: 36752589
DOI: 10.1021/acs.biochem.2c00666
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.47 Å)
構造検証レポート
Validation report summary of 7p85
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon